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Abstract
Objective: Poor adherence to complex multimodal
therapies is a widely recognized problem in the daily
care of dialysis patients, contributing to excess mor-
bidity and mortality of this population. While a few
studies have been devoted to understanding patient
nonadherence, their results were somewhat controver-
sial. The goals of this review are to quantify nonad-
herence to certain oral medications, to raise awareness
of factors that may cause problems in a patient`s ad-
herence to this treatment, and to describe strategies
that may be used to improve adherence to prescribed
pharmacotherapy.
Methods: A systematic literature review in the
MEDLINE and PubMed database (1971-2008) was
performed. Quantitative studies, which accurately indi-
cated the total percentages of nonadherence to oral
medication in adult patients receiving chronic he-
modialysis, were identified.
Results: A total of 19 studies fulfilled the search crite-
ria. Rates of nonadherence to the oral medication
ranged from 3 - 80%. More than half of the included
studies reported nonadherence rates of ≥ 50% (mean
67%). The use of phosphate binding therapy was the
prevalent surveyed oral medication. Self reports,
structured interviews, and predialysis serum phos-
phate levels were the most frequent assessment tools
used to record adherence rates. Limitations of the re-
viewed studies included small patient cohorts, incon-
sistent definitions of adherence, and a lack of stan-
dardized methods for measuring nonadherence.
Conclusions: Nonadherence to oral medication in he-
modialysis patients is still an underestimated, but life-
threatening behaviour.
Key words: Adherence, compliance, hemodialysis,
medication, prescription
INTRODUCTION
The prevalence and incidence of chronic kidney dis-
ease stage V (end-stage renal disease) are continuously
increasing, particularly in elderly patients [1]. End-
stage renal disease (ESRD) is not simply a mono-or-
gan failure, but rather a systemic disorder affecting a
number of other organ systems. Despite significant
advances in the technology of renal replacement ther-
apy (RRT), no current modality of blood purification
serves as a substitute for all renal functions. RRT un-
doubtedly contributes to long-term survival. However,
morbidity and mortality of maintenance dialysis pa-
tients remain high: only about one third of the US he-
modialysis (HD) patients are alive after 5 years [2].
Cardiovascular diseases are the leading cause of death
in ESRD patients [3]. Notably, patients with ESRD
have a very high prevalence of cardiovascular disease
risk factors such as diabetes and hypertension, but
they are also exposed to other non-traditional, uremia-
related cardiovascular disease risk factors, particularly
derangements in calcium and phosphate metabolism
[4]. Given the complexity of these cardiovascular risk
factors in ESRD patients, it presents a challenging tar-
get for therapy. To modify these risk factors such as
hypertension or secondary hyperparathyroidism, the
HD patient has to take an average of 6-12 tablets per
day [5, 6, 7].
Successful RRT of ESRD patients relies on patient
adherence to various aspects of the therapy, such as
attendance to the number of sessions prescribed to
achieve the optimal dose of RRT, restriction of fluid
intake, following dietary guidelines, and adherence to
complex medical regimens [8, 9, 10, 11]. There is solid
evidence that adherence of ESRD patients correlates
with morbidity and mortality [12]. Specifically, skip-
ping treatment and poor dietary adherence are strong-
ly associated with greater risk for death [13]. Unfortu-
nately, poor adherence (compliance) with prescribed
medication is a widely recognized problem in daily
practice, but few studies have been devoted to under-
standing patient nonadherence to medication [14].
Furthermore, criteria to assess nonadherence to pre-
scribed oral medications are often arbitrary and are
not linked to defined clinical outcomes.
The goals of this literature review are: i) to quantify
nonadherence to drugs preventing or treating sec-
ondary hyperparathyroidism, or to antihypertensive
drugs, ii) to raise awareness of factors that may cause
problems in patient adherence to these treatment pro-
grams, and iii) to describe strategies that may be used
to improve adherence to prescribed medication.
MATERIALS AND METHODS
We conducted a systematic literature review in the on-
line databases MEDLINE and PubMed (1971-2008)
using a comprehensive list of relevant search terms
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medication/drug, dialysis/hemodialysis, renal replace-
ment therapy, end-stage renal disease/chronic renal fail-
ure) to identify studies on oral medication adherence
among adult HD patients. We limited our review to
those articles that accurately indicated total percentages
or rates of nonadherence to oral medication in the HD
population. The systematic literature research identified
a total of 387 published articles that contained a com-
bination of the search terms in the abstract. The vast
majority (368) of these articles were qualitative studies,
review articles, or case reports. Articles focusing on pe-
diatric adherence (patients under 18 years of age) were
excluded.
RESULTS
Only 19 studies reported total rates of nonadherence
to oral medication among adult HD patients. Key in-
formation is summarized in Table 1.
The selected articles showed a wide variation with
regard to the sample size, varying from a minimum of
19 patients [15] to a maximum of 6251 patients [16].
Seven out of 19 studies (37%) included a total number
of less than 50 patients.
Phosphate binders (PB, 18/19 studies), antihyper-
tensive drugs (AHT, 11/19 studies), or oral calcium
supplementation including the vitamin D analog cal-
citriol (CAS, 8/19 studies) were the prevalent surveyed
oral medications.
Self reports or structured interviews (patient self
reports, PSR, 16/19 studies, 84%) were the most fre-
quently used tools to assess adherence rates. Predialy-
sis serum phosphate (9/19 studies, 47%) was com-
monly used as an adherence indicator for patients tak-
ing the oral prescribed phosphate binding medication.
Limit values for predialytic phosphate levels showed a
broad amplitude from >4.5 mg/dl [15] to >7.5 mg/dl
[16]. Only two studies by Curtin and coworkers [17, 6]
used medication event monitoring devices (MEMS) to
monitor patientﾴs adherence.
Quantitative rates of nonadherence to oral medica-
tion substantially varied in the reviewed studies, and
estimates of the percentage of nonadherent partici-
pants ranged from 3 - 80%. More than half of the in-
cluded studies (11/19, 58%) reported nonadherence
rates of ≥ 50% (mean 67%).
A history of long-term HD [18], older age (>65
years) [17], higher educational level [19], lower medica-
tion costs [20, 21], as well as little concerns about po-
tential adverse effects were identified as markers for
adherence. Among psychosocial variables an internal
locus of control orientation (defined as a high expec-
tation that one`s actions have a causal relationship
with the produced consequences) [15] and perceived
barriers were most significantly associated with good
adherence [22].
DISCUSSION
To determine the frequency and prevalence of nonad-
herence in patients with ESRD undergoing HD, a
clear-cut and consistent definition of these terms is
essentially needed.
Owing to the inconsistencies in uniform defini-
tions, widely divergent results have been obtained in
different studies, so that as many as 80% of HD pa-
tients may be considered noncompliant with oral med-
ication [23, 24, 8, 18]. The data of the selected 19
studies revealed that the calculated median is closer to
50% [25].
Standardized adherence parameters that can be easi-
ly measured and verified would be desirable to achieve
reproducible and accurate rates of nonadherence.
Nonadherence rates to oral medication are most fre-
quently assessed by predialytic serum phosphate levels.
However, serum phosphate level is not only influ-
enced by the phosphate binder therapy itself, but also
by diet restrictions, dialysis attendance and residual re-
nal function, revealing the lack of specificity particu-
larly in regard to comorbid illness and the patient`s
nutritional status. This could be a possible explanation
for the weak correlations between adherence rates es-
timated by self reports and phosphate measurements.
To date, there is little consensus among researchers
about standardized methods for measuring nonadher-
ence. Assessment tools for evaluation of adherence in
the HD population include direct and indirect moni-
toring methods (summarized in Table 2).
Microelectronic monitoring devices (MEMS) [26]
are recently introduced microchips incorporated into
drug container caps and offer a reliable and objective
source of adherence data [27, 28]. MEMS are expen-
sive, but monitoring 1 or 2 medications, chosen as
“sentinel” drugs, is usually sufficient to determine ad-
herence [26, 29]. Marked differences in rates of non-
adherence as measured by the MEMS versus self re-
ports were observed: MEMS recorded 52% of the
HD patients as repeatedly nonadherent for antihyper-
tensive medication and 70% as repeatedly noncompli-
ant for phosphate binder medication, whereas evalua-
tion of self reports only identified 12% and 8%, re-
spectively [17, 6].
Factors associated with nonadherence in HD pa-
tients, mainly based on expert opinion, are similar to
those for other chronic conditions and can be subdi-
vided into demographic, clinical and psychosocial pre-
dictors (summarized in Table 3) [30].
Among the most frequently assessed demographic
predictors of oral medication adherence, age seems to
be a strong predictor of nonadherence in patients with
ESRD undergoing HD in most, albeit not all studies.
Some articles reported that older age, particularly > 65
years, was associated with higher levels of adherence
[31, 32, 24, 33, 23, 34]. This is in contrast to recent ob-
servations, reporting an emerging cognitive impairment
and dementia in the aging dialysis population [35, 36].
The complexity of the prescribed medication regi-
men is another crucial predictor of nonadherence, as
prescribed number of doses seems to be inversely re-
lated to adherence [26]. Unfortunately, once-daily dos-
ing as latterly introduced in the therapy for HIV-in-
fected patients as well as for transplant recipients is
unrealistic for the multimorbid adult HD patient [37,
38].
In addition to treatment complexity and high pill
burden, also the size and taste of phosphate binding
tablets may impact adherence to prescribed oral med-
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Table 1. Studies in a chronological order focusing on adherence to prescribed oral medication in adult HD patients.
Study, year Included Medication % Non- Nonadherence Results
patients type adherent definition
/assessment
Wenerowicz, 19 PB 60 P >4.5 mg/dl Patients with internal locus of control1
1978 [15] PSR (questionnaire) orientation showed higher compliance
than with external locus
Cummings, 116 PB 70 P >5.5 mg/dl Situational factors and psychosocial
1982 [51] PSR (interview) variables major contributors to adherence
Betts, 1988 46 PB 74 P >5 mg/dl Length of time on HD, age, educational
[52] PSR (questionnaire) level and response to illness not signifi-
cantly related to adherence
Weed-Collins, 30 PB 64 P >5.5 mg/dl Perceived barriers (“forgetting” and “be-
1989 [22] PSR (questionnaire) ing away from home”) most significant
predictors of compliance, women signifi-
cantly more compliant
Blanchard, 40 PB, CAS, Vits 28 PSR Majority of HD patients knew dosing
1990 (53) (questionnaire) schedules but knowledge about drug
treatment was grossly deficient
Bame, 1993 1230 PB, AHT, 50 P >6.0 mg/dl Prevalence of noncompliance consistent
[23] CAS with previous studies; older age and high-
er income associated with compliance
Kaplan, 1994 30 PB, AHT 67 PSR (questionnaire) Drug selection and medication compli-
[7] Reporting missing a ance contained greatest number of poten-
dose tial problems
Cleary, 1995 51 AHT, PB, 61 P >4.5 mg/dl Patients with long-term HD more com-
[18] CAS, Vits (interview) pliant with AHT and CAS than with PB
Lin, 1997 [54] 86 PB, CAS 24 – 61 P >4.59 mg/dl, Multidimensional Health Locus of Con-
PSR, nurses` trol (MHLC) scale had only slight influ-
assessment ence on measures of compliance
Curtin, 1997 135 AHT, PB 42 – 80 MEMS Patients ≤ 65 yrs made more dosing
[17] errors with AHT and missed taking PB
on more days than patients > 65 yrs
Leggat, 1998 6251 PB 22 P >7.5 mg/dl Younger patients and smokers with high-
[16] er rates of noncompliance; blacks signifi-
cantly less noncompliant than whites
Curtin, 1999 135 AHT, PB 73 PSR, pill count, African-Americans with higher rates of
[6] MEMS noncompliance
Caraballo 53 AHT, PB, CAS75 PSR, Reporting Significant association between compli-
Nazario, 2001 missing a dose ance and educational level
(19) (structured interview)
Horne, 2001 47 AHT, PB, CAS57 PSR, Nonadherence correlated with concerns
[55] Reporting missing a about potential adverse effects of medica-
dose (self report) tion
Tomasello, 129 PB 38-51 PSR (taking < 80% Compliance did not account for the large
2004 [56] of medication), P difference in prescribed pill burden
>5.5 mg/dl
Rahman, 205 AHT 23 PSR, Reporting Good adherence to AHT therapy
2004 [57] missing a dose
Holley, 2006 39 AHT, PB 21 PSR, Inadequate prescription coverage, lack of
[20] Reporting missing a transportation, and medication cost con-
dose (structured tribute to noncompliance
interview)
Lindberg, 144 AHT, PB, 80 Discrepancy Deviation between consumption and pre-
2007 [58] CAS, Vits between self-report scription in chronic HD patients
and medication list
Hirth, 2008 5478 AHT, PB, 3 *- 29 ** Reporting costre- Cost-related nonadherence varies across
[21] CAS lated nonadherence countries, substantial international varia-
(questionnaire) tion
Abbreviations: PB Phosphate binder, AHT Antihypertensives, CAS Ca supplements including calcitriol, Vits Vitamins, MEMS
medication event monitoring system, * Japan, ** USA; 1defined as a high expectation that one`s actions have a causal relation-
ship with the produced consequences
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phate binding in ESRD patients could circumvent
high pill burden in the future. If the calcium- and alu-
minium-free lanthanum carbonate could provide ef-
fective phosphate control with a lower tablet burden
has to be elucidated [40].
HD patients are commonly affected by secondary
hyperparathyroidism (SHPT), in which 3 well-known
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Table 2. Standard assessment tools for evaluation of adherence in the HD population.
Direct monitoring methods Indirect monitoring methods
assays of drug concentrations in biological fluids patient self-reports (structured interviews, questionnaire)
use of markers incorporated into pills compliance ratings by nurses
direct observation of pill taking prescription refills
pill counts
microelectronic monitoring devices (MEMS)
Table 3. Factors associated with nonadherence in HD patients.
Demographic factors age
sex / gender
educational level
marital status / living arrangements
race / ethnicity
income / employment status
cost / payment / insurance / socioeconomic situation
smoking / drinking / drug abuse
religion / religiosity
Clinical factors length of time on hemodialysis
chronicity / chronic conditions
diabetic status
former transplant history
treatment regimen complexity / high tablet burden
tablet size and taste
treatment side effects
Psychosocial factors health beliefs / knowledge / motivation
self-esteem
cognitive behaviour / function
health locus of control1
social support and family dynamics
psychiatric illness anxiety / depression
coping style
patient-physician relationship
1defined as a high expectation that one`s actions have a causal relationship with the produced consequences.
Note: These factors are mainly based on expert opinion.
Table 4. Strategies to improve HD patient`s adherence to oral medication.
Improvement of interaction with the attending physicians and the nursing staff
Maintenance of contact with the patient and the patient`s family (empathy on adherence, trust)
Continuous education of the patient about the disease and its treatment
Establishment of the goals of therapy
Improvement of patient motivation
Awareness of medication-taking behaviour
Reduced complexity of treatment regimens (once-a-day formulations)
Early diagnosis of cognitive impairment
Note: While interventional studies are lacking in the HD population, the proposed strategies are predominantly based on expert
opinion.
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phatemia, and calcitriol deficiency. Anecdotal reports
showed that HD patients who receive any injectable
vitamin D formulation have a survival advantage over
comparable patients who receive no injectable vitamin
D [41]. The intravenous administration of vitamin D
or vitamin D analogs should further improve adher-
ence in therapy for SHPT in HD patients. Several new
vitamin D analogs, e.g. paricalcitol (19-nor-1,25(OH)
2D2), have been developed and investigated with the
rationale to treat SHPT with a reduced risk of hyper-
calcemia and hyperphosphatemia [42].
Psychosocial variables, such as the extent of de-
pression [43] and social support or family dynamics
[44], are frequently related to outcome in ESRD pa-
tients treated with HD [45]. Particularly in regard to
prescribed oral medication, an internal locus of con-
trol orientation [15] and perceived barriers (especially
forgetting and being away from home) were significant
predictors of compliance [22].
Patient motivation, empathy and trust are essential
key factors to optimize patient adherence. As stated in
“The Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure” [46], the “most effective thera-
py prescribed by the most careful clinician will control the
disease only if the patients are motivated”. In the devel-
opment of empathy, attending physicians and the
nephrology nursing staff play a pivotal role. Particular-
ly, nephrology nurses are ideally placed to establish a
partnership with the chronic HD patient [11]. The HD
patient requires consistent and repeated education
about their disease, treatment, and risks and benefits of
adherence [47]. Interventional studies evaluating possi-
ble strategies to improve prescribed oral medication ad-
herence are so far lacking in the dialysis population [48].
However, a single structured drug education program
for HD patients yielded significant increases in medica-
tion knowledge and adherence within a control group
[49]. To minimize nonadherence, interventions need to
focus on both patient factors and the extent to which
relationships and system problems compromise the pa-
tientﾴs ability to adhere to medication treatment [50].
Taken together, a wide spectrum of useful strategies
to improve medication adherence have been proposed,
but most of them were not proved by interventional
studies (summarized in Table 4). A patient-centered
approach, including the removal of barriers to adher-
ence, with improved communication, simplification of
medication regimen, ongoing education, and the use of
MEMS have been recommended as strategies to im-
prove medication adherence. However, up to now, no
single strategy has been definitely proven to yield uni-
versal and/or long lasting improvements in adherence.
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